



## **Aldeyra Therapeutics to Present at the Oppenheimer & Co. 30th Annual Healthcare Conference**

March 3, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that David McMullin, Chief Commercial Officer of Aldeyra, will present at Oppenheimer & Co.'s 30<sup>th</sup> Annual Healthcare Conference in New York City. The presentation is scheduled to begin at 10:55 a.m. (ET) Tuesday, March 17, 2020.

A live webcast of the presentation can be accessed on the "Investors & Media" section of the Aldeyra website, <https://ir.aldeyra.com/>. An audio replay will be available following the live presentation and will be archived on the website for 90 days.

### ***About Aldeyra Therapeutics***

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are potential first-in-class treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200303005212/en/): <https://www.businesswire.com/news/home/20200303005212/en/>

### **Corporate Contact:**

David McMullin  
Aldeyra Therapeutics, Inc.  
Tel: 781-761-4904 ext. 218  
[dmcullin@aldeyra.com](mailto:dmcullin@aldeyra.com)

### **Investor & Media Contact:**

Scott Solomon  
Sharon Merrill Associates, Inc.  
Tel: 617-542-5300  
[ALDX@investorrelations.com](mailto:ALDX@investorrelations.com)

Source: Aldeyra Therapeutics, Inc.